AMO Pharma reveals data from myotonic dystrophy study
Clinically significant results have emerged from trial evaluating the company’s AMO-02 candidate
Read More
Tag: AMO
J&J snaps of Abbott’s eye unit for $4.36bn
Johnson & Johnson is buying Abbott’s eye health unit in a cash deal worth $4.36 billion, building on its presence in the area and marking its entry into cataract surgery.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
